Drug intelligence / Profile preview

KBLP-010

Development stage: Preclinical
Lead developer: KoBioLabs
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

KBLP-010 is a drug candidate under development by KoBioLabs for the treatment of autism spectrum disorder. It is currently in preclinical development. The drug is part of KoBioLabs’ portfolio focused on innovative therapies based on live biotherapeutic products and effector molecules for immune, metabolic, and neurological diseases[6][3]. The specific mechanism of action has not been publicly detailed beyond its association with microbiome-based or live biotherapeutic approaches.

Beyond the preview

Go deeper on KBLP-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBLP-010.

Explore the full profile